Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Herr

Showing results (251-260 of 278) with videos related to

Pageof 28
Sort By:
Critical Care Medicine|July 14, 2021
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter StudyCristina Gutierrez, Anne Rain T Brown, Heather P May, et al.
Blood Cancer Discovery|February 2, 2026
Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsMackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe, et al.
Transplantation and Cellular Therapy|July 7, 2022
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort StudyNeel S Bhatt, Akshay Sharma, Andrew St Martin, et al.
British Journal of Cancer|June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerA F Hezel, M S Noel, J N Allen, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
Journal of Pathology Informatics|November 26, 2015
Practical considerations in genomic decision support: The eMERGE experienceTimothy M Herr, Suzette J Bielinski, Erwin Bottinger, et al.
Blood Advances|October 22, 2025
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortiumMegan Melody, Natalie Grover, Stephanie Franco, et al.
Medchemcomm|August 16, 2018
Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profileK Futatsugi, K Huard, D W Kung, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Journal of Critical Care|May 4, 2020
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicitiesCristina Gutierrez, Anne Rain T Brown, Megan M Herr, et al.
Pageof 28

Showing results (251-260 of 278) with videos related to

Sort By:
Pageof 28
Critical Care Medicine|July 14, 2021
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter StudyCristina Gutierrez, Anne Rain T Brown, Heather P May, et al.
Blood Cancer Discovery|February 2, 2026
Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsMackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe, et al.
Transplantation and Cellular Therapy|July 7, 2022
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort StudyNeel S Bhatt, Akshay Sharma, Andrew St Martin, et al.
British Journal of Cancer|June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerA F Hezel, M S Noel, J N Allen, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
Journal of Pathology Informatics|November 26, 2015
Practical considerations in genomic decision support: The eMERGE experienceTimothy M Herr, Suzette J Bielinski, Erwin Bottinger, et al.
Blood Advances|October 22, 2025
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortiumMegan Melody, Natalie Grover, Stephanie Franco, et al.
Medchemcomm|August 16, 2018
Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profileK Futatsugi, K Huard, D W Kung, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Journal of Critical Care|May 4, 2020
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicitiesCristina Gutierrez, Anne Rain T Brown, Megan M Herr, et al.
Pageof 28